title: Fabry disease in patients with migraine with aura.
abstract: Anderson-Fabry disease (AFD) is an X-linked recessive lysosomal disease caused by alpha-galactosidase A (alpha-gal) deficiency, causing progressive glycosphingolipid storage in various organ systems. Headache is a frequent symptom. Cerebral magnetic resonance imaging (MRI) often shows multiple white matter lesions (WML), like those seen in patients affected by migraine, in particular with aura (MA). To our knowledge, there are no reports about the prevalence of AFD in patients with MA. The objective of the study was to determine AFD prevalence, as assessed by alpha-gal activity and genetic tests, in MA patients. We evaluated 73 consecutive patients followed by the Headache Centre of our Department with a diagnosis of MA. They were screened for migraine characteristics and cerebrovascular risk factors. Gaseous contrast transcranial Doppler was used to diagnose right-to-left shunt and MRI to detect WML. All patients underwent blood test to evaluate peripheral alpha-gal activity and to identify alpha-gal gene mutations. Of 73 consecutive screened subjects (59 females, 14 males; mean age 38.3 +/- 11.8 years), the known GLA pathologic mutation p.[Asp313Tyr] was found in a 38-year-old woman, with a history of MA, deep venous thrombosis and abdominal pain. Cerebral MRI showed small WML. This is the first study reporting AFD prevalence in a cohort of MA patients. We found a relatively high prevalence (about 1.37%) among the examined patients, even if this finding needs to be confirmed in a larger sample. Despite this high prevalence, it seems not necessary to screen systematically all MA patients for AFD, but since it is a treatable genetic disorder, it is worthwhile to consider it for the subgroup of patients presenting WML and other typical AFD symptoms.
authors.affiliation: Department of Neuroscience, Ophthalmology and Genetics, University of Genova, Genoa, Italy. beatricealbano@yahoo.it
authors.forename: Beatrice
authors.initials: B
authors.lastname: Albano
authors.forename: L
authors.initials: L
authors.lastname: Dinia
authors.forename: M
authors.initials: M
authors.lastname: Del Sette
authors.forename: C
authors.initials: C
authors.lastname: Gandolfo
authors.forename: G
authors.initials: G
authors.lastname: Sivori
authors.forename: C
authors.initials: C
authors.lastname: Finocchi
mesh_terms: D000328:Adult; D015897:Comorbidity; D000795:Fabry Disease / Q000000981:diagnostic imaging / Q000453:epidemiology* / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020325:Migraine with Aura / Q000000981:diagnostic imaging / Q000453:epidemiology*; D009154:Mutation; D015995:Prevalence; D017585:Ultrasonography, Doppler, Transcranial; D000519:alpha-Galactosidase / Q000235:genetics
chemical_list: D000519:alpha-Galactosidase
references.citation: Lancet Neurol. 2006 Sep;5(9):791-5
references.pmid: 16914407
references.citation: Lancet. 2005 Nov 19;366(9499):1794-6
references.pmid: 16298216
references.citation: Eur J Pediatr. 2003 Nov;162(11):767-72
references.pmid: 14505049
references.citation: BMC Neurol. 2002 Jun 18;2:4
references.pmid: 12079501
references.citation: Pain Res Manag. 2006 Autumn;11(3):185-92
references.pmid: 16960635
references.citation: Stroke. 2009 Mar;40(3):788-94
references.pmid: 19150871
references.citation: Stroke. 2002 Feb;33(2):525-31
references.pmid: 11823664
references.citation: BMJ. 2005 Jan 8;330(7482):63
references.pmid: 15596418
references.citation: Arch Neurol. 2004 Sep;61(9):1366-8
references.pmid: 15364681
references.citation: Eur J Clin Invest. 2004 Mar;34(3):236-42
references.pmid: 15025684
references.citation: Cephalalgia. 2004;24 Suppl 1:9-160
references.pmid: 14979299